Revised IWG Definitions Aim to Clarify Treatment Outcomes in Immune-Mediated TTP
Researchers attempted to revise clinically relevant definitions for patients with iTTP in light of recent changes.
Diagnosis & Disease Information
Novel Assay Shows Promise for ADAMTS13 Activity Evaluation in Thrombotic Thrombocytopenic Purpura
A novel assay for evaluating ADAMTS13 activity may be both fast and reliable for the diagnosis of thrombotic thrombocytopenic purpura (TTP), according to the results of a study published in Research and Practice in Thrombosis and Hemostasis. A thrombotic microangiopathy that can be life-threatening, TTP can be diagnosed only through measurement of ADAMTS13 activity, which…
Venous Thromboembolism May Be More Likely in Patients With Thrombocytopenic Purpura
A single-institution chart review of patients with TTP showed evidence that they may be at higher risk for VTE; therefore, there may be a need to implement VTE thromboprophylaxis earlier for hospitalized patients.
Implications of the von Willebrand Factor-ADAMTS13 Axis With COVID-19
A letter to the editor drew attention to the increased risk of thrombotic disorder for patients with severe COVID-19, which seems to occur by interacting with the von Willebrand Factor-ADAMTS13 axis.
iTTP: Older Age, Hypertension, and Smoking Linked With Increased Stroke Risk
A team of researchers sought to determine the frequency of and risk factors associated with ischemic stroke in patients with immune thrombotic thrombocytopenic purpura.
Biomarkers Reveal Patients at Greater Risk of Death in Immune Thrombotic Thrombocytopenic Purpura
Researchers identified predictive markers — including plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA — for the pathogenesis of and prognosis for patients with iTTP.
Increased Mortality Rate Seen in Survivors of Thrombotic Thrombocytopenic Purpura
A 2-fold increase in mortality was seen among patients with thrombotic thrombocytopenic purpura compared with the general US population.
Cyclophosphamide in Treatment of Immune Thrombotic Thrombocytopenic Purpura
A retrospective analysis showed similar outcomes for cyclophosphamide as seen with rituximab in treatment of immune thrombotic thrombocytopenic purpura.
Real-World Study of Caplacizumab for Thrombotic Thrombocytopenic Purpura
A retrospective analysis shows that real-world outcomes with caplacizumab for thrombotic thrombocytopenic purpura are similar to clinical trial results.
Thrombotic Thrombocytopenic Purpura: Triplet Therapy May Prevent Unfavorable Outcomes
Caplacizumab with therapeutic plasma exchange and immunosuppression appears to prevent unfavorable clinical outcomes in patients with immune-mediated TTP.
- Loading...
Loading...
Next post in Thrombotic Disorders
Loading... 
Loading...